A present disclosure describes about an improved form of purified crystalline sodium nitrite. The said form of sodium nitrite may comprise a purity level between 99% to 99.2%. The form of sodium nitrite may also comprise an amount of sodium nitrate no greater than 0.7%. The present disclosure also relates to a method of obtaining an improved form of purified crystalline sodium nitrite with minimum impurities.

A present disclosure describes about an improved form of purified crystalline sodium nitrite. The said form of sodium nitrite may comprise a purity level between 99% to 99.2%. The form of sodium nitrite may also comprise an amount of sodium nitrate no greater than 0.7%. The present disclosure also relates to a method of obtaining an improved form of purified crystalline sodium nitrite with minimum impurities.

Disclosed is a composition and method for neutralization of hydrogen sulfide and light mercaptanes from hydrocarbon media, and improvement of the copper strip indicator in petroleum products. The composition is an aqueous solution of polysulfides comprising alkali metals and/or polysulfides of primary or secondary ethanolamines, alkali metal hydroxides, water-soluble alkylamines and optionally alkali metal nitrites.

Disclosed is a composition and method for neutralization of hydrogen sulfide and light mercaptanes from hydrocarbon media, and improvement of the copper strip indicator in petroleum products. The composition is an aqueous solution of polysulfides comprising alkali metals and/or polysulfides of primary or secondary ethanolamines, alkali metal hydroxides, water-soluble alkylamines and optionally alkali metal nitrites.

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO.sub.2.sup.). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO.sub.2.sup.). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.

The present disclosure generally relates to implantable devices including a releasable nitrite ion and to methods of preparing and using such compositions and devices. In one embodiment, the device is a stent, for example, a vascular stent. In another embodiment, the nitrite ion is ionically bound to an inorganic ion.

The present disclosure generally relates to implantable devices including a releasable nitrite ion and to methods of preparing and using such compositions and devices. In one embodiment, the device is a stent, for example, a vascular stent. In another embodiment, the nitrite ion is ionically bound to an inorganic ion.

Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.

Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.